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Abstract
Genetic research has shown that mutations that modify the protein-coding
sequence of ATP1A3, the gene encoding the α3 subunit of Na(+)/K(+)-ATPase,
cause both rapid-onset dystonia parkinsonism and alternating hemiplegia of
childhood. These discoveries link two clinically distinct neurological diseases to
the same gene, however, ATP1A3 mutations are, with one exception, disease-
specific. Although the exact mechanism of how these mutations lead to disease is
still unknown, much knowledge has been gained about functional consequences
of ATP1A3 mutations using a range of in-vitro and animal model systems, and
the role of Na(+)/K(+)-ATPases in the brain. Researchers and clinicians are
attempting to further characterise neurological manifestations associated with
mutations in ATP1A3, and to build on the existing molecular knowledge to
understand how specific mutations can lead to different diseases.
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Distinct neurological disorders with ATP1A3 mutations
Erin L Heinzen, Alexis Arzimanoglou, Allison Brashear, Steven J Clapcote, Fiorella Gurrieri, David B Goldstein, Sigurður H Jóhannesson, 
Mohamad A Mikati, Brian Neville, Sophie Nicole, Laurie J Ozelius, Hanne Poulsen, Tsveta Schyns, Kathleen J Sweadner, Arn van den Maagdenberg, 
Bente Vilsen, for the ATP1A3 Working Group
Genetic research has shown that mutations that modify the protein-coding sequence of ATP1A3, the gene encoding the 
α3 subunit of Na+/K+-ATPase, cause both rapid-onset dystonia parkinsonism and alternating hemiplegia of childhood. 
These discoveries link two clinically distinct neurological diseases to the same gene, however, ATP1A3 mutations are, 
with one exception, disease-speciﬁ c. Although the exact mechanism of how these mutations lead to disease is still 
unknown, much knowledge has been gained about functional consequences of ATP1A3 mutations using a range of in-
vitro and animal model systems, and the role of Na+/K+-ATPases in the brain. Researchers and clinicians are attempting 
to further characterise neurological manifestations associated with mutations in ATP1A3, and to build on the existing 
molecular knowledge to understand how speciﬁ c mutations can lead to diﬀ erent diseases.
Introduction
The introduction of next-generation sequencing tech-
nology, which allows nearly complete assessment of 
human exomes and genomes, has signiﬁ cantly boosted 
gene discovery.1 These gene discoveries have advanced our 
knowledge of disease-speciﬁ c pathophysiology, and have 
enabled genetic connections to be made between diseases. 
An example is the recent identiﬁ cation of mutations in 
ATP1A3, a gene previously associated with rapid-onset 
dystonia parkinsonism (RDP), in alternating hemiplegia 
of childhood (AHC). This genetic connection between 
diseases oﬀ ers unique research opportunities to explore 
how genetics governs speciﬁ c clinical phenotypes, and to 
study the underlying pathophysiology.
Here, we review current knowledge of the roles of 
ATP1A3 in the brain, as well as the phenotypes associated 
with mutations in the gene. Finally, we discuss additional 
research needed to further characterise the full 
phenotypic spectrum associated with mutations in 
ATP1A3 and the associated changes in protein function, 
to establish possible strategies for the development of 
new treatments for AHC, RDP, and related disorders.
Roles of Na+/K+-ATPases
Na+/K+-ATPases are membrane-bound transporters that 
harness the energy of ATP hydrolysis to move three Na+ 
out of the cell in exchange for two K+ ions moving 
inwards. The resulting ionic gradients establish 
membrane potentials that generate electrical impulses 
and move neurotransmitters and Ca2+ across the plasma 
membrane. Na+/K+-ATPases consist of catalytic α, β, and 
regulatory γ subunits (ﬁ gure 1). The main role of the α 
subunit is to bind and transport Na+ and K+. There are 
four α subunits, all encoded by diﬀ erent genes. The α3 
subunit, encoded by ATP1A3, is the predominant α 
subunit expressed in neurons,2–4 although many neurons 
also express α1. The α3 subunit diﬀ ers from α1 in that it 
has a comparatively low aﬃ  nity for Na+ and K+,5,6 which 
enables rapid normalisation of ion gradients after intense 
neuronal ﬁ ring. Changes in the activity of Na+/K+-
ATPases in neurons (predominantly expressing α3) have 
physiological consequences. For example, inhibition of 
Na+/K+-ATPases in the thalamus converts neuronal 
bursting responses to single spike discharges.7 In the 
hippocampus, reduction of the activity of Na+/K+-ATPase 
causes interictal epileptiform bursting activity.8 
Furthermore, localisation of α3 in dendritic spines has 
been shown to play a part in controlling the size and 
speed of the small depolarisations caused by ﬂ uctuations 
of intracellular Na+ that occur during activation of ion-
gating neurotransmitter receptors. These ﬂ uctuations, 
known as transients, are summated in dendrites and are 
the basis of synaptic integration.9–11
In addition to its primary function in ion transport, 
subunits of Na+/K+-ATPases have been shown to interact 
with proteins that assist in localisation of enzymes to the 
cell membrane, modulate the PI3K, PLCγ, and MAPK 
signal transduction cascades, and regulate the activity of 
other transporters and receptors.12 The protein–protein 
interactions speciﬁ c to the α3 subunit are not fully 
characterised, but, as an example, the α3 isoform has been 
shown in rat neurons to bind speciﬁ cally to PSD95, a 
scaﬀ olding protein that organises proteins at the synapse.10
ATP1A3 mutations and neurological disorders
In 1999, two large families were identiﬁ ed with several 
members presenting with RDP.13,14 Linkage analyses 
identiﬁ ed the 19q13 locus as the region most likely to 
harbour mutations associated with disease;15 a ﬁ nding 
that was conﬁ rmed in additional families with RDP.16,17 
RDP in all these families was inherited as an autosomal 
dominant trait with incomplete penetrance. Using a 
positional cloning approach, investigators identiﬁ ed six 
diﬀ erent heterozygous missense mutations in ATP1A3 
that co-segregated with the disease phenotype.18 Since 
the initial discovery, 11 mutations (nine missense 
mutations, a 3-bp in-frame deletion, and a 3-bp in-frame 
insertion; ﬁ gure 2; table 118–34) have been reported in 
20 patients with RDP, 12 of whom had a positive family 
history of the disease.17–30,35 Three mutations, one found 
only in sporadic RDP cases and two found in both 
sporadic and familial RDP cases, are recurrent, probably 
because they are located at hypermutable methylated 
CpG-dinucleotides in ATP1A3 (table 1).36
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In 2012, two independent studies, one by an inter-
national consortium31 and one by German researchers,32 
identiﬁ ed de-novo mutations in ATP1A3 as the cause of 
AHC. In both studies next-generation sequencing was 
used to screen the protein-coding portion of the genome 
of patients with sporadic AHC to look for disease-causing 
mutations that were absent in their unaﬀ ected parents. 
This approach identiﬁ ed a de-novo ATP1A3 mutation in 
each of the ten initial patients screened in the two studies 
combined, which deﬁ nitively establishes ATP1A3 as the 
ﬁ rst AHC gene.31,32 This ﬁ nding was replicated in an 
independent Japanese study,33 which found ATP1A3 
mutations in eight of ten patients with AHC. The German 
study identiﬁ ed mutations in all 24 German patients with 
AHC.32 Notably, the international study reported ATP1A3 
mutations in 82 (78%) of 105 patients with AHC,31 which 
suggests that some ATP1A3 mutations might have been 
missed, that other AHC genes might exist, or that the 
diagnosis might not always be accurate. 27 diﬀ erent 
ATP1A3 mutations have been reported in patients with 
AHC (ﬁ gure 2, table 1). Ten mutations have been identiﬁ ed 
in more than one individual, with one mutation 
(Asp801Asn) explaining more than 40% of AHC cases 
with an ATP1A3 mutation (table 1).
When we consider the location in the ATP1A3 protein 
sequence of mutations that cause RDP or AHC, an 
interesting diﬀ erence emerges. Whereas RDP mutations 
seem to be spread across the protein, AHC mutations are 
located almost exclusively in particular regions of the 
protein (ﬁ gure 3). The signiﬁ cance of the diﬀ erent 
mutation patterns in RDP and AHC is currently unknown, 
but suggests that, unlike in RDP, only speciﬁ c protein 
disruptions result in AHC. Additionally, rarely the same 
aminoacid is mutated in RDP and AHC, but even in these 
cases the aminoacid substitution is disease-speciﬁ c 
(table 1). Only one RDP mutation (Asp923Asn) has also 
been identiﬁ ed in an unusual case of familial AHC. In 
this multiplex AHC family, four individuals have the 
Asp923Asn mutation, including one with a diagnosis of 
AHC and three with some of the deﬁ ning symptoms of 
AHC (see below).29 This nearly perfect genotype-phenotype 
correlation, with a nearly non-overlapping set of mutations 
associated with AHC or RDP, strongly argues for a distinct 
functional eﬀ ect of the mutations causing AHC or RDP, 
which is yet to be elucidated.
Consistent with mutations in ATP1A3 causing 
neurodevelopmental diseases, only two polymorphic 
missense mutations (both with low population frequencies 
[minor allele frequency <0·1%]) have been reported for 
ATP1A3 (ﬁ gure 2, table 1) in the Exome Variant Server, 
NHLBI GO Exome Sequencing Project (Seattle, WA, 
USA). The database houses variants from protein-coding 
genomes of approximately 6500 individuals who were not 
identiﬁ ed based on neurodevelopmental or neuro-
psychiatric disease phenotypes. Evaluating the relationship 
of the total number of polymorphic functional variants as 
a function of the total number of variants for each 
Figure 1: Structure of the 
Na+/K+-ATPase
(A) The Na+/K+-ATPase in the 
potassium-occluded state 
showing K+ (red spheres), the 
three protein subunits α (grey 
lines), β (purple line) and 
FXYDγ (green line), and 
phosphorylation, which is 
mimicked by MgF4² (dark grey 
spheres). Residues reported to 
be mutated in AHC or RDP, or 
both, are indicated by spheres 
at the α carbon, yellow for one 
case of AHC, orange for more 
than one case of AHC, cyan for 
RDP, and green for both AHC 
and RDP. Key ion binding 
residues are shown in stick 
format. (B) A 90° degree 
rotation in the membrane 
plane of the representation 
shown in (A), giving an 
extracellular view of the 
ion-binding transmembrane 
part of the Na⁺/K⁺-ATPase with 
disease-causing mutations 
colour coded as in (A). Two of 
the ion-binding residues 
(shown in sticks) have been 
found to be mutated both in 
patients with RDP and in those 
with AHC. Figures made from 








































www.thelancet.com/neurology   Vol 13   May 2014 505
Review
sequenced gene in the database indicates that observing 
two polymorphic functional variants in ATP1A3 given the 
total number of variants reported is less that what is 
expected. Thus, ATP1A3 is generally intolerant of 
functional variation in comparison with genome-wide 
expectations for a gene of its size and mutability, implying 
that individuals with functional mutations in this gene 
might be at high risk of developing serious diseases.37
Rapid-onset dystonia parkinsonism
Recognition of RDP began in 1993, more than 10 years 
before ATP1A3 was identiﬁ ed as the causal gene, when 
Dobyns and colleagues14 reported a 15-year-old girl who 
had abrupt onset of dystonia with prominent dysarthria 
and dysphagia. The disorder was named RDP because of 
the abrupt onset of dystonic spasms associated with 
postural instability and bradykinesia that resemble signs 
of parkinsonism.13,38–40 RDP is also sometimes referred to 
as dystonia 12 (DYT12; OMIM: 128235). ATP1A3 is the 
only known RDP gene; however, other RDP genes might 
exist, as evidenced by one study reporting that, in a select 
group of 14 patients referred for possible RDP, only three 
had a mutation in ATP1A3.19
The clinical presentation of RDP includes three features: 
its appearance, which often occurs after triggering events 
such as running, alcohol binges, minor head injuries, 
overheating, emotional stress, infections, or childbirth;21 a 
rapid onset of typically permanent symptoms that develop 
over hours to days (occasionally even over several weeks); 
and involuntary movements that are characterised by 
generalised dystonia with superimposed parkinsonian 
features (primarily bradykinesia and postural instability 
without tremor). Many patients present with a rostrocaudal 
gradient of dystonia and parkinsonism, in the sense that 
bulbar symptoms are more severe than arm symptoms, 
and arm symptoms are more severe than leg symptoms. 
The bulbar and arm symptoms rarely improve after the 
primary disease onset. A few patients have reported later 
episodes of abrupt worsening of symptoms that occurred 
from 1 year to as late as 9 years after the initial onset. One 
patient, who had transient symptoms after athletic activity, 
recovered, resumed strenuous athletic activity, and then 
had permanent onset of ﬁ xed symptoms. Not all patients 
report a recognised trigger, and a few report antecedent 
periods of cramping. Patients typically lack other disease 
features such as diurnal ﬂ uctuation or episodes of 
symptoms that are typical of patients with AHC. 
A recently published cohort of 26 patients with RDP 
indicated that 76% had onset of motor symptoms by the 
age of 25 years.41 In addition to dystonia, patients can also 
have non-motor manifestations. Recent work suggests 
that patients with RDP have an increased prevalence of 
mood disorders (50%) and psychosis (19%) compared 
with relatives without an ATP1A3 mutation.41 These 
ﬁ ndings were observed across families with diﬀ erent 
ATP1A3 mutations, and are consistent with reports of 
depression in individuals with ATP1A3 mutations 
causing motor problems.16
The originally published diagnostic criteria for RDP 
require a family history, an onset of the disease in teenage 
years, and prominent bulbar ﬁ ndings.19 However, as the 
number of reported cases of RDP increases, these criteria 
seem too restrictive for several reasons: more than half of 
patients with RDP lack a positive family history because 
the disease is caused by de-novo mutations in small, 
single-patient families; disease onset has been reported 
in children and adults;30 and recognition is growing that 
there are patients in whom RDP can present with atypical 
Figure 2: Location of AHC-causing or RDP-causing mutations in ATP1A3 gene, mRNA, and protein
Red dots show AHC-causing mutations and blue dots show RDP-causing mutations. The one mutation shared between disease phenotypes is located at Asp923Asn (blue dot with a red dot inside). 
Two rare polymorphisms identiﬁ ed in the general population but not associated with a disease at this time are indicated by green dots. AHC=alternating hemiplegia of childhood. RDP=rapid-onset 
dystonia parkinsonism. aa=aminoacids. nt=nucleotides. bp=basepairs.
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features, including second onsets and unusual, mild-to-
moderate improvement after the primary onset of disease 
symptoms (table 2). Collectively, these ﬁ ndings suggest 
that the phenotype is broader than originally described 
in 1993. 
Drug therapy in RDP is limited; patients are 
unresponsive to standard drugs for parkinsonism, 
including levodopa.14,16,19,20,41 Current treatment is limited 
to benzodiazepines, which have been reported to provide 
symptomatic relief in some patients. 
Alternating hemiplegia of childhood
Although the ﬁ rst report of AHC was by Verret and 
Steele in 1971,60 it was not until 1980 that Krageloh and 
Aicardi61 ﬁ rst deﬁ ned the syndrome. In 1993, the speciﬁ c 
clinical criteria to diagnose AHC were proposed.42 
These, named the Aicardi criteria, include seven disease 
features: (1) paroxysmal episodes of hemiplegia; (2) 
episodes of bilateral hemiplegia or quadriplegia; (3) 
other paroxysmal manifestations, such as abnormal eye 
movements, dystonia, nystagmus, intermittent strabi-
smus, tonic spells, or autonomic disturbance, which 
can occur during hemiplegia or as isolated events; (4) 
evidence of permanent neurological dysfunction, which 
can manifest as intellectual deﬁ ciencies, seizures, 
ataxia, choreoathetosis, develop mental delay, or 
persistent motor deﬁ cits such as spastic diplegia or 
quadriplegia or hypotonia; (5) inducing sleep during a 
paroxysmal attack might relieve symptoms for a period 
of time after awakening; (6) ﬁ rst signs of dysfunction 
occurring before age 18 months; and (7) not being 
attributed to other disorders. The median age of disease 
onset of the ﬁ rst paroxysmal event is 3·5 months with a 
range from the ﬁ rst day of life to 4 years. Developmental 
delay might not appear until after 12 months. Additional 
clinical details are summarised in table 2.
Although nearly all cases of AHC are sporadic, some 
families have an autosomal dominant inheritance of the 
disorder.49–51,62 In two families a causal ATP1A3 mutation 
was identiﬁ ed,29,31,62 and in one family a disease-causing 
ATP1A2 (encoding the α2 subunit of the Na+/K+-ATPase) 
mutation was found.50,51 Consistent with these mutations 
being highly penetrant, all ATP1A2 or ATP1A3 mutation 
Disease Disease inheritance Number of unrelated 
patients with the 
mutation*
410C→T; Ser137Phe AHC Sporadic 1
410C→A; Ser137Tyr AHC Sporadic 2
419A→T; Gln140Leu AHC Sporadic 1
821T→A; Ile274Asn AHC Sporadic, familial 2
821T→C; Ile274Thr RDP Sporadic 1
829G→A; Glu277Lys RDP Sporadic 2




998G→T; Cys333Phe AHC Sporadic 2
1112T→C; Leu371Pro AHC Sporadic 1
1838C→T; Thr613Met RDP Sporadic, familial 6
2051C→T; Ser684Phe RDP Sporadic 1
2263G→T; Gly755Cys AHC Sporadic 2
2263G→A; Gly755Ser AHC Sporadic 1
2267G→A; Arg756His RDP Sporadic 1
2273T→G; Ile758Ser RDP Familial 1
2316C→A; Ser772Arg AHC Sporadic 1
2318A→T; Asn773Ile AHC Sporadic 1
2318A→G; Asn773Ser AHC Sporadic 1
2338T→C; Phe780Leu RDP Familial 1
2401G→A; Asp801Asn AHC Sporadic 49
2401G→T; Asp801Tyr RDP Familial 1
2403T→A; Asp801Glu AHC Sporadic 1
2417T→G; Met806Arg AHC Sporadic 1
2429T→G; Ile810Ser AHC Sporadic 1
2431T→C; Ser811Pro AHC Sporadic 4
2443G→A; Glu815Lys AHC Sporadic 31




2767G→A; Asp923Asn RDP, AHC Sporadic and familial 
RDP, familial AHC
RDP sporadic, 2; RDP 
familial, 2; AHC familial, 1
2767G→T; Asp923Tyr AHC Sporadic 1
2780G→A; Cys927Tyr AHC Sporadic 1
2839G→A; Gly947Arg AHC Sporadic 5
2839G→C; Gly947Arg AHC Sporadic 2
2864C→A; Ala955Asp AHC Sporadic 1




 ATP1A3 mutation coordinates are deﬁ ned based on UniProt ID P13637 and Consensus CDS ID CCDS12594·1. Mutation 
658G→A, Asp220Asn, previously reported as causal by Heinzen and coworkers31 was later shown to be a rare, inherited 
mutation, and the disease-causing mutation in this patient was a previously overlooked de-novo Asp801Asn ATP1A3 
mutation (unpublished data); thus Asp220Asn is not shown in this table and one additional patient has been counted 
as having an Asp801Asn mutation. AHC=alternating hemiplegia of childhood. RDP=rapid-onset dystonia parkinsonism. 
*Compiled from references.18–34
Table 1: Disease-causing ATP1A3 mutations
Figure 3: Density plot showing the distribution of AHC and RDP mutations in 
ATP1A3
Mutations identiﬁ ed to date in 20 patients with RDP (blue) and 118 patients 
with AHC (red). In general, RDP mutations appear more evenly distributed, 
whereas AHC mutations are heavily concentrated in particular sites in the 
protein. AHC=alternating hemiplegia of childhood. RDP=rapid-onset dystonia 
parkinsonism. Aminoacid positions are based on the ATP1A3 protein deﬁ ned by 
UniProt ID P13637.
Aminoacid position in ATP1A3
RDP
AHC
0 200 400 600 800 1000
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carriers in these families have symptoms of AHC, albeit 
to varying severity even within families.29,31,50,51,62 In 
addition to these unusual familial cases, other patients 
have atypical presentations that resemble AHC, although 
currently a role for ATP1A3 mutation is untested. These 
include benign nocturnal alternating hemiplegia, which 
occurs only in boys,52,53 mild cases with normal cognitive 
development,54 cases in which dystonia is the 
predominant feature,54 patients who do not have episodes 
of quadriplegia, patients who have the ﬁ rst signs of the 
disorder after the age of 18 months,54,55 patients presenting 
with neonatal seizures, and patients with status 
epilepticus with associated long-term atrophy on MRI 
and residual motor and eye movement abnormalities.56
Over the years, patients with AHC have undergone 
many treatments to alleviate the frequency and severity 
of hemiplegia, although success has been very limited.43,44 
Flunarizine, a calcium channel blocker, performed best 
because it seemed to reduce the severity and duration of 
attacks, at least in some patients.45–48 Benzodiazepines, 
which increase the activity of GABA, the major inhibitory 
neurotransmitter in the CNS, might also have some 
eﬃ  cacy either directly or by inducing sleep, which often 
relieves attacks.43,44
Genotype–phenotype correlation
Although the number of patients with AHC or RDP with 
an identiﬁ ed ATP1A3 mutation is rapidly growing, 
deﬁ nitive phenotypic patterns have not been found for 
patients with and without mutations, and in patients 
with recurring ATP1A3 mutations.31,32,34 However, one 
small study63 evaluating the phenotypes of 35 patients 
with AHC with ATP1A3 mutations reports that patients 
with the Glu815Lys mutation tend to have earlier onset of 
symptoms, more severe motor and cognitive disabilities, 
and more often report status epilepticus and respiratory 
paralysis compared with patients with AHC with other 
ATP1A3 mutations. This preliminary ﬁ nding suggests 
that genotype–phenotype correlations exist and that 
additional studies will be needed to further evaluate 
these patterns in larger sample sizes. The ATP1A3 
Working Group is currently analysing genotype–
phenotype correlations in 150 patients.
Biological eﬀ ects of ATP1A3 mutations
In-vitro studies
ATP1A3 protein expression and localisation
Ten RDP and ﬁ ve AHC ATP1A3 mutations have been 
investigated at the level of protein expression and cellular 
localisation of the protein by using heterologous expression 
systems.18,31 These studies revealed that for all except two of 
the tested RDP mutations the ATP1A3 protein expression 
was reduced, whereas none of the AHC mutations reduced 
expression of ATP1A3. RDP mutations were not shown to 
aﬀ ect the maturation and localisation of the protein in 
transfected cells;18 the eﬀ ect of AHC mutations on ATP1A3 
localisation has not yet been studied.
ATP1A3 mutations in platelets and ﬁ broblasts
Platelets and ﬁ broblasts from nine patients with AHC 
have been screened for diﬀ erences in protein expression 
compared with age-matched and sex-matched controls.64 
A consistent increase in the level of activated lysosomal 
protein cathepsin B was observed in specimens from 
patients with AHC, which was shown to increase 
apoptosis. Although the mechanism remains unclear, 
AHC RDP
Age of onset 0–18 months (median 3·5 months), although some isolated cases are reported as late as 4 years Can occur in children and adults (9 months to 
59 years); 76% of patients report symptoms by 
age 25 years
Inheritance Typically sporadic; rare cases of familial AHC Sporadic or familial
Clinical presentation Paroxysmal symptoms: episodes of hemiplegia, bilateral hemiplegia, or quadriplegia with improvement in sleep and 
with other paroxysmal abnormalities such as dystonia, tonic spells, epileptic seizures (seizures occur in about 50% of 
patients and can include focal or generalised tonic, tonic-clonic, or myoclonic seizure types), autonomic changes, or 
abnormal eye movements (including unilateral [ipsilateral to the hemiplegia] intermittent eye deviation, disconjugate 
gaze, and pendular nystagmus) often with the following characteristics: common triggers include stress, excitement, 
extreme heat or cold, water exposure, physical exertion, lighting changes, and foods; variable frequency ranging from 
multiple episodes per day to one every few months; associated with anarthria, dysphagia, and autonomic disturbances 
including bradycardia, stridor, bronchospasm, apnoea, dyspnoea, nausea, unilateral or bilateral ﬂ ushing, hypothermia 
or hyperthermia; episodes typically remit with sleep, but can return within 10–20 min after waking; episodes of 
dystonia in concert or separate from episodes of hemiplegia, bilateral hemiplegia, quadriplegia, or abnormal eye 
movements that are more commonly observed early in the clinical course, typically consist of head turning toward the 
aﬀ ected side with eye deviations toward the same side; very brief intense unilateral or bilateral tonic or dystonic attacks 
with vibratory tremor and pain
Interictal symptoms: evidence of developmental delay (including intellectual deﬁ ciencies, neuropsychological 
deﬁ cits), mental retardation, and interictal neurological abnormalities such as tone abnormalities, choreoathetosis 
(spontaneous or movement-induced), or ataxia (sometimes associated with cerebellar atrophy or cerebellar 
hypometabolism), and persistent motor deﬁ cits (such as spastic diplegia or quadriplegia, hypotonia)
Typically abrupt onset of permanent symptoms 
of generalised dystonia and parkinsonian features 
including bradykinesia and postural instability
Variable progression of symptoms ranging from 
hours to weeks
Diurnal ﬂ uctuation or episodes typical of patients 
with AHC are not seen in RDP
Abrupt worsening of symptoms can rarely occur 
years after initial onset
Onset of symptoms typically occurs after running, 
alcohol binges, minor head injuries, overheating, 
emotional stress, infections, or childbirth
Can be associated with mood disorders and psychosis
Drug therapy Flunarizine, benzodiazepines Unresponsive to levodopa
AHC=alternating hemiplegia of childhood. RDP=rapid-onset dystonia parkinsonism.
Table 2: Proposed diagnostic criteria for AHC and RDP13,14,16,19,20,29–31,38–59
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this work suggests that similar protein changes might 
also occur in the brain and could contribute to AHC 
pathophysiology.
Na+/K+-ATPase activity
In the established Post-Albers model for the Na+/K+-
ATPase transport mechanism (ﬁ gure 4),65 in which three 
cytoplasmic Na+ ions are exchanged for two extracellular 
K+ ions for each ATP being hydrolysed, the E1 conformation 
preferentially binds Na+, whereas E2 preferentially binds 
K+. On the basis of this model, there are several 
experimental approaches to measure the activity of the 
Na+/K+-ATPase, and speciﬁ cally the eﬀ ects of disease-
causing mutations in ATP1A3 on the catalytic cycle.
First, using a luminescent kinase assay that measures 
ADP formed from each catalytic cycle of the Na+/K+-
ATPase (ﬁ gure 4) from cells heterologously expressing 
the wild-type, RDP-causing, or AHC-causing mutant 
version of the ATP1A3 cDNA, investigators have shown 
that each mutation reduced the activity of the Na+/K+-
ATPase.31 These ﬁ ndings, coupled with the afore-
mentioned protein expression analyses, suggest that 
mutations that aﬀ ect Na+/K+-ATPase function, but not 
the amount of Na+/K+-ATPase per se, seem to result in 
the more severe AHC phenotype.
Second, since active Na+/K+-ATPase pumps a net charge 
of +1 out of the cell for each round of the catalytic cycle 
(ﬁ gure 4), electrophysiology-based approaches can be 
used to measure, in a living cell or in a patch of excised 
membrane, the voltage and ion sensitivity of the pump 
during steady-state activity. Two disease-causing ATP1A3 
mutations have been characterised in detail: Asp801Asn 
and Asp923Asn. The aspartate located at aminoacid 
position 801 is highly conserved in Na+/K+-ATPases in all 
investigated species, and is a site that binds either the 
Na+ or K+ ions during the catalytic cycle. Expression of the 
AHC-causing Asp801Asn mutant in Xenopus oocytes 
showed that the mutation did not generate any 
measurable pump current, consistent with it being 
unable to bind K+ ions.67 Analysis of the Asp923Asn 
mutation, which was identiﬁ ed in both patients with 
RDP23,25,29,30 and familial AHC,29 suggested that 
protonation at this site was crucial for the movement of 
Na+ and K+ across the cell membrane.68
Third, during the ion transport process, the Na+/K+-
ATPase becomes phosphorylated by transfer of the 
γ-phosphate of ATP to a conserved aspartic acid residue in 
the P-type ATPase signature sequence (ﬁ gure 4). By 
incubating ATP radiolabelled at the γ-phosphate with cell 
membrane fragments containing the Na+/K+-ATPase to 
quantify this covalent and acid-stable phosphoryl bond, 
investigators can measure the activity of the Na+/K+-ATPase 
with and without disease-causing mutations.66,69–71 Because 
the binding of three Na+ ions at the cytoplasmic surface of 
the ATP1A3 protein is needed to activate the enzyme for 
phosphorylation from ATP, the aﬃ  nity for Na+ at these 
sites can be established by measurement of the Na+ 
dependence of phosphorylation, the aﬃ  nity being deﬁ ned 
by the Na+ concentration giving half maximum phosph-
orylation. So far, RDP-causing mutations Glu277Lys, 
Thr613Met, Phe780Leu, +Tyr (an extension of the 
C-terminus with an extra Tyr residue), and the RDP-
causing and AHC-causing mutation Asp923Asn have 
been characterised with these methods.24,69–71 Each of the 
mutations shows striking reductions of Na+ aﬃ  nity for 
activation of phosphorylation. Whereas Na+ binding from 
the cytoplasmic side activates phosphorylation from ATP, 
binding of K+ from the external side triggers de-
phosphorylation, thereby stimulating ATP hydrolysis. 
Therefore, the aﬃ  nity for external K+ can be established by 
study of the K+ dependence of dephosphorylation or 
ATPase activity at a ﬁ xed Na+ concentration. Notably, none 
of the mutants show a reduced aﬃ  nity for K+, indicating a 
selective disturbance of Na+ binding that is associated with 
mutations causing RDP and one mutation causing AHC 
(Asp923Asn).66,69–71
The described studies show that a selective reduction 
of the aﬃ  nity of the Na+/K+-ATPase for cytoplasmic Na+ 
without disturbance of K+ binding is a central feature 
in RDP. Consequently, increased intracellular Na+ 
concentration resulting from the reduced Na+ aﬃ  nity 
could be a key pathogenic factor in RDP.66 A rise in 
intracellular Na+ might result in a secondary increase 
in intracellular Ca²+ via the Na+/Ca²+ exchange system, 
which can activate signalling cascades triggered by 
changes in Ca²+ concentration. Additionally, a 
disturbance of the Na+ gradient could aﬀ ect the uptake 
of neurotransmitters such as dopamine and glutamate. 
Because several AHC-causing mutations target the 
same residue (Ile274, Asp801, Asp923) as the one 
mutated in RDP, an essential question to address is 
whether Na+ aﬃ  nity is also typically disturbed in AHC. 
The aﬃ  nity for K+ might also be disturbed in AHC, 
which could also explain why AHC is at the severe end 
of the phenotypic spectrum, whereas RDP is at the 
Figure 4: Post-Albers model65 for the Na+/K+-ATPase reaction cycle
Reproduced from Toustrup-Jensen and coworkers66 with permission from the 
American Society for Biochemistry and Molecular Biology. E1 and E2 are major 
conformational states with preference for binding of Na⁺ and K⁺, respectively. 
Cytoplasmic and extracellular ions are indicated by subscripts c and e, 
respectively. Brackets indicate occlusion of the ions in a cavity in the protein. 
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mild end. Structural modelling of three AHC-causing 
mutations (Ile274Asn, Asp801Asn, and Asp923Tyr) and 
three RDP-causing mutations (Ile274Thr, Asp801Tyr, 
and Asp923Asn) that aﬀ ect identical positions in the 
Na+/K+-ATPase α3 subunit72 predicted that AHC 
mutations would bring about structural changes that 
severely aﬀ ect eﬃ  cient K+ movement along the narrow 
K+ access pathway. Instead, RDP-causing mutations 
seem to have milder structural consequences that are 
likely to result in a milder impairment of K+ 
movement.73
Notably, a mutation in the sarcoendoplasmic reticulum 
Ca²+ ATPase, a member of the same type II P-type ATPase 
family as the Na+/K+-ATPase, in Drosophila melanogaster 
causes temperature-sensitive ionic leakage of the 
transporter.74 Investigators postulated that a temperature-
sensitive gain-of-function mechanism might also 
underlie the phenotypic consequences of disease-causing 
mutations in other type II P-type ATPases, including 
ATP1A3 in AHC and RDP. Although the eﬀ ect of 
temperature on the functional eﬀ ects of AHC-causing 
and RDP-causing mutations in Na+/K+-ATPases is 
unknown, if correct, this mechanism could explain why 
environmental triggers such as stress, physical exertion, 
and temperature changes can lead to symptom onset in 
patients with RDP or AHC (table 2).
Animal studies
Myshkin mice
Several animal models have been used to study the in-
vivo consequences of ATP1A3 modulation (ﬁ gure 5). The 
aminoacid sequence identity between the human and 
mouse Na+/K+-ATPase α3 subunits is about 99%. 
Heterozygous Myshkin (Atp1a3Myk/+; Myk/+) mutant mice 
have an aminoacid change (Ile810Asn) that aﬀ ects the 
identical position to Ile810Ser in the human Na+/K+-
ATPase α3 subunit that was identiﬁ ed in a patient with 
AHC.31,75 Molecular modelling of Ile810Asn and Ile810Ser 
showed that both changes bring about similarly severe 
structural eﬀ ects on the Na+/K+-ATPase α3 subunit, 
including the capacity for eﬃ  cient K+ movement along 
the K+ access pathway.73 Ile810Asn was generated through 
N-nitroso-N-ethylurea (ENU) mutagenesis and results in 
a normally expressed, but inactive, α3 protein and a 
subsequent 36–42% reduction in total Na+/K+-ATPase 
activity (reﬂ ecting the combined activity of α1, α2, and α3) 
in the brain.75,81
Heterozygous Myk/+ mice have an unsteady, tremulous 
gait with occasional splaying of the hindlimbs, but without 
an overt hemiplegia.73 Phenotypic analysis revealed a 
range of other abnormalities in Myk/+ mice, including 
reduction in body size, motor deﬁ cits in the balance beam 
and rotarod tests, cognitive deﬁ cits in the fear-conditioning 
Figure 5: Na+/K+-ATPase α3 genetic animal models
(A) Atp1α3 mutant mice. The locations of three mutations in the mouse Atp1a3 genomic locus are depicted. Myshkin mice carry a T→A transversion in exon 18 that results in the substitution of 
asparagine for isoleucine at position 810 (Ile810Asn).73,75 Atp1a3tm1Ling mice carry a point mutation in intron 4 adjacent to the exon-intron splice site that results in aberrant splicing of the gene, adding 
126 bp to the RNA transcript.75–77 Atp1a3tm2Kwk mice carry a STOP-polyA cassette that replaces exons 2–6 in Atp1a3.78 (B) Atpα mutant Drosophila. AtpαCJ10 fruit ﬂ ies carry a G→A transition that results in 
the substitution of glycine for serine at position 744 (Gly744Ser).79 Gly744Ser in the Drosophila α subunit is equivalent to mutation Gly755Ser in the human α3 subunit found in a patient with AHC.31 
(C) atp1a3a/b knockdown zebraﬁ sh. Knockdown of atp1a3a or atp1a3b RNA transcript by around 65% in 60 hpf embryos had similar phenotypic eﬀ ects.80 Red stars show point mutations. NKA=Na+K+-
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and conditioned taste aversion tests, neuronal hyper-
excitability with spontaneous convulsions, and mania-
related behaviours such as increased risk-taking and 
responsiveness to treatment with lithium and valproic 
acid.73,75,81 When subjected to vestibular stress, Myk/+ mice 
have transient tonic attacks and staggering movements 
that, in a third of mice, develop into tonic-clonic seizures 
that are accompanied by epileptiform discharges.75 ¹⁴C-2-
deoxyglucose imaging of Myk/+ mice identiﬁ ed 
compromised thalamocortical functioning, including a 
deﬁ cit in frontal cortex functioning and reduced 
thalamocortical functional connectivity.73 When bred to 
homozygosity, Myk/Myk pups die shortly after birth.75
Strategies aimed at increasing Na+/K+-ATPase activity 
have shown some therapeutic eﬀ ects in Myk/+ mice. 
Transgenic delivery of an additional copy of the wild-type 
Atp1a3 gene to the X chromosome increased Na+/K+-
ATPase α3 subunit protein expression and whole brain 
Na+/K+-ATPase activity, and reduced the epileptic seizure 
susceptibility as well as the risk-taking behaviour of 
Myk/+ mice.75,82 Chronic treatment with rostafuroxin, a 
compound that antagonises the inhibitory action of 
ouabain on Na+/K+-ATPase,83 was also found to reduce 
the risk-taking behaviour of Myk/+ mice.81 Eﬀ ects of this 
intervention on the motor and cognitive deﬁ cits of Myk/+ 
mice have not yet been established.
Atp1a3tm1Ling mice
Heterozygous Atp1a3tm1Ling/+ mice, which have a point 
mutation in intron 4 of the Atp1a3 gene, show a reduction 
of hippocampal α3 protein expression of around 60% and 
a reduction of total brain Na+/K+-ATPase activity (of α1, α2, 
and α3 combined) of around 16%.75,76,82 Non-stressed 
(naive) Atp1a3tm1Ling/+ mice do not have visible neurological 
defects or restricted growth, but instead show increased 
locomotor activity in an open ﬁ eld test and deﬁ cient 
spatial learning in the Morris water maze test.76 After 
exposure to restraint stress for 5 days, female Atp1a3tm1Ling/+ 
mice show mild motor deﬁ cits in the balance beam and 
rotarod tests.77 Atp1a3tm1Ling/+ mice exposed to chronic 
variable stress, consisting of one or two unpredictable 
mild stressors per day for 6 weeks, have deﬁ cits in total 
brain Na+/K+-ATPase activity, sociability, and object 
recognition memory, as well as increased anxiety and 
depression-like behaviours, compared with non-stressed 
Atp1a3tm1Ling/+ mice.82 In Atp1a3 wild-type mice, chronic 
variable stress also led to depression-like behaviour and 
reduced sociability, but had no eﬀ ect on Na+/K+-ATPase 
activity, anxiety, or object recognition memory compared 
with non-stressed wild-type controls.82 Homozygous 
Atp1a3tm1Ling pups die shortly after birth.76
Atp1a3tm2Kwk mice
Heterozygous Atp1a3tm2Kwk/+ mice have a targeted deletion 
of Atp1a3 exons 2–6.78 Atp1a3tm2Kwk/+ mice do not show gross 
morphological defects or apparent histological brain 
anomalies. Adult male Atp1a3tm2Kwk/+ mice show increased 
locomotor activity, both in the home cage and in the open 
ﬁ eld test. By contrast with Atp1a3Myk/+ mice, Atp1a3tm2Kwk/+ 
mice had improved performance in the balance beam and 
rotarod tests compared with wild-type mice. Atp1a3tm2Kwk/+ 
mice do not develop dystonia spontaneously, nor after 
various stressors, such as tail suspension, forced 
swimming, or restraint. Dystonia can be induced 
pharmacologically84 in these mice by injection of the 
neuroexcitatory aminoacid kainate directly into the 
cerebellum. The response to dystonia induction by kainate 
injection was increased in Atp1a3tm2Kwk/+ mice, with a longer 
duration of sustained dystonia compared with wild-type 
mice. Electrophysiological studies showed that inhibitory 
neurotransmission at molecular-layer interneuron 
Purkinje cell synapses was increased in the cerebellar 
cortex of Atp1a3tm2Kwk/+ mice. Homozygous Atp1a3tm2Kwk mice 
show a complete lack of breathing movements and die 
shortly after birth.78
Pharmacological blockade of Na+/K+-ATPase α3
Perfusion of the Na+/K+-ATPase inhibitor ouabain into the 
cerebellum and basal ganglia was found to induce mild 
dyskinesia in wild-type C57BL/6 mice.85 When mice were 
subsequently exposed for 2 h to stress provided in the 
form of random electric foot shocks in a warm 
environment (38°C), 70% of the mice developed persistent 
dystonia and rigidity.85 These mice show hallmark 
symptoms of RDP, including dystonia and parkinsonism 
induced by stress. However, this approach is limited by 
the similar aﬃ  nities of the α2 and α3 isoforms for 
ouabain,86 thus precluding α3 speciﬁ city in this animal 
model.
Zebraﬁ sh
Zebraﬁ sh (Danio rerio) have two ATP1A3 orthologues, 
atp1a3a and atp1a3b.87 The paralogous α3a and α3b subunits 
have aminoacid identities of 95% with each other and 
91–92% with the human Na+/K+-ATPase α3 subunit 
protein sequence. Consistent with mammalian Na+/K+-
ATPase α3 subunit protein expression, the transcripts of 
atp1a3a and atp1a3b are primarily expressed in the brain, 
albeit with distinct expression proﬁ les. In 60 h post-
fertilisation zebraﬁ sh embryos, the atp1a3a transcript is 
widely distributed throughout the brain, whereas 
distribution of atp1a3b mRNA is localised to particular 
brain structures. Despite having distinct expression 
proﬁ les, targeted knockdown of atp1a3a or atp1a3b by 
morpholino antisense oligonucleotides results in severe 
brain ventricle dilation in 60 h post-fertilisation embryos, 
suggesting that both α3 paralogues are needed for brain 
ventricle maintenance. The extent of brain ventricle 
dilation was reduced by co-injection of the mRNA of the 
knocked-down gene, but atp1a3b mRNA did not cross-
rescue the phenotype of atp1a3a-knockdown embryos. 
Similarly, atp1a3a mRNA did not cross-rescue the 
phenotype of atp1a3b-knockdown embryos. Both 
morphants display abnormal spontaneous motility and 
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an abnormal response to tactile stimulation with a 
needle,80 suggesting that both α3 paralogues are needed 
for embryonic motility.
Drosophila
The gene Atpα (FlyBase ID: FBgn0002921) in Drosophila 
melanogaster fruit ﬂ ies encodes the α subunit of the 
Na+/K+-ATPase, which is orthologous to all vertebrate α 
subunits, and has aminoacid sequence identities of 
76–77% with the α1, α2, and α3 subunits of human beings.88 
Although the Drosophila Atpα gene is not a speciﬁ c 
orthologue of ATP1A3, eight missense mutations, 
generated through ethylmethanesulfonate mutagenesis at 
highly conserved aminoacid residues, lead to AHC-
relevant phenotypic abnormalities in adult heterozygous 
ﬂ ies.79,89 Flies from any of six lines with mutations 
(Ser201Leu, Pro262Leu, Ser348Thr, Gly528Ser, Ala588Thr, 
Gly744Ser) in Atpα that were repeatedly knocked to the 
bottom of a vial using a standard laboratory vortexer 
showed transient mechanical stress-induced paralysis.79 
Two other mutant lines (Asp981Asn, Glu928Lys) did not 
show this phenotype when maintained at an ambient 
temperature of 20–22°C, but showed temperature-
sensitive mechanical stress-induced paralysis when 
maintained at 28°C.89 When exposed to a temperature of 
37–38°C, three mutant lines (Gly744Ser, Asp981Asn, 
Glu928Lys) showed temperature-sensitive paralysis that 
was reversed when the ambient temperature was lowered 
to 20–22°C.79,89 When the bodyweight of male ﬂ ies of six of 
the same mutant lines was measured, only Ser201Leu 
mutant ﬂ ies showed a reduction compared with wild-type 
ﬂ ies.79 Western blotting of homogenised ﬂ y heads showed 
that the expression of Na+/K+-ATPase α subunit was 
reduced in two of the Atpα mutants (Ser348Thr, 
Ala588Thr), but unchanged in the other four mutants.79 
Mutations Gly744Ser and Asp981Asn in the Drosophila α 
subunit, which led to temperature-sensitive paralysis, 
aﬀ ect equivalent aminoacid residues in the human 
Na+/K+-ATPase α3 subunit, namely mutations Gly755Cys, 
Gly755Ser, and Asp992Tyr, which were identiﬁ ed in 
patients with AHC (table 3).31,32 All eight missense 
mutations are homozygous lethal.79
Conclusions
Since the original descriptions of RDP and AHC, 
substantial work has been done to characterise their 
clinical presentation and pathophysiology. Through the 
identiﬁ cation of disease-causing mutations in ATP1A3, 
these two seemingly unrelated diseases are now linked, 
allowing new opportunities to obtain insight into their 
biological bases.
We now understand that protein-modifying genetic 
variations in ATP1A3 rarely occur in the general population 
and, when they do, the risk of severe neurological disease 
is very high. This understanding has led to a new research 
area, investigating which other diseases might be 
associated with mutations in ATP1A3. One could postulate 
that ATP1A3 mutations might also be found in patients 
with seizures, psychiatric conditions, or other less severe 
types of dystonia or ataxia. As next-generation sequencing 
becomes widely used in day-to-day clinical practice, the 
role of ATP1A3 mutations in a wider range of phenotypes 
might become apparent. However, as this genotype–
phenotype spectrum is being deﬁ ned, we can already 
begin cataloguing ATP1A3 disease-speciﬁ c mutations and 
polymorphic protein-disrupting variants in the general 
population, to establish molecular and physiological 
changes associated with these DNA variations in in-vitro 
and in-vivo test paradigms like those described in this 
Review. Data from these studies can be used to develop 
better research models with tiered complexity. We envisage 
that these studies will include establishing disease models 
at the transporter level in individual cells, multicellular 
network models using induced pluripotent cells 
diﬀ erentiated into neurons, ex-vivo studies in brain slices 
to study tissue-level eﬀ ects, and, ﬁ nally, evaluations at the 
organism level to assess in-vivo consequences in animal 
models. With these model systems we can begin to relate 
molecular changes to the phenotypic presentations 
associated with these disorders, including the episodic 
nature of AHC, how particular stimuli lead to the onset of 
symptoms, the age-dependent onset of RDP, and the 
variable eﬀ ects on organ systems and brain structures that 











Ser201Leu Ser212 No Yes ↓ No change
Pro262Leu Pro273 No Yes No change No change
Ser348Thr Ser359 No Yes No change ↓
Gly528Ser Gly539 No Yes No change No change
Ala588Thr Ala599 No Yes No change ↓
Gly744Ser Gly755, AHC Yes Yes No change No change
Asp981Asn Asp992, AHC Yes Mild ND No change
Glu982Lys Asp993 Yes Mild ND No change
Adapted from Ashmore and colleagues.79 AHC=equivalent aminoacid residue that is substituted in alternating 
hemiplegia of childhood. Mild=when maintained at 28°C. No change=no change from wild-type. ↓=lower than 
wild-type. ND=not determined.
Table 3: Drosophila Na+/K+-ATPase α subunit mutant phenotypes
Search strategy and selection criteria
References cited in this Review were identiﬁ ed through 
PubMed searches using the search terms “ATP1A3”, “alternating 
hemiplegia of childhood”, “rapid-onset dystonia parkinsonism”, 
and “Na,K-ATPase “, from December, 1993, until January, 2014. 
Articles were identiﬁ ed through searches of the reference lists of 
the articles found with the above cited search terms and of the 
authors’ own ﬁ les. All references used in this Review were 
published in English, and were selected according to originality 
and relevance to the content of this Review.
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Importantly, once key biomarkers of disease patho-
physiology are identiﬁ ed, we will be able to screen for 
compounds to rectify the pathophysiological changes 
associated with ATP1A3 mutations.
In summary, genetics has illuminated key aspects of 
disease pathophysiology for both AHC and RDP. 
Although extensive work is needed to disentangle the 
complex biology underlying these disorders, we are 
poised with evolving research approaches to rapidly 
translate these genetic discoveries to detailed disease 
pathophysiology, to improve understanding of develop-
mentally mediated and environmentally triggered 
disease presentation, and ultimately to develop treat-
ments for these debilitating diseases.
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